The American Society of Radiologic Technologists has launched its new educational series, Image-guided Radiation Therapy.

Agfa HealthCare announces today that under the theme of "Images without Boundaries," the company will launch new products and advanced technologies at the Radiological Society of North America (RSNA) annual meeting in Chicago, December 1 - 5, 2013.  An imaging leader with thousands of DR/CR, PACS, and a full range of product installations at healthcare facilities across the globe, Agfa HealthCare is focused on enabling greater healthcare efficiencies and productivity. Continuing its commitment to workflow-centric solutions, the company will introduce new offerings that break down the barriers between departments and hospital groups along the care continuum, and further advance meaningful use of the EHR.    Agfa HealthCare announces today that under the theme of "Images without Boundaries," the company will launch new products and advanced technologies at the Radiological Society of North America (RSNA) annual meeting in Chicago, December 1 - 5, 2013.  An imaging leader with thousands of DR/CR, PACS, and a full range of product installations at healthcare facilities across the globe, Agfa HealthCare is focused on enabling greater healthcare efficiencies and productivity. Continuing its commitment to workflow-centric solutions, the company will introduce new offerings that break down the barriers between departments and hospital groups along the care continuum, and further advance meaningful use of the EHR.

MedCurrent Corporation, a leading provider of clinical decision support systems, today announced the debut of OrderRight 3.0 at the Radiological Society of North America’s Annual Meeting (RSNA), December 1 - 5, 2013 at Chicago’s McCormick Place. MedCurrent will exhibit in the South Hall, booth # 3106.

Intelerad Medical Systems™, a leader in medical imaging PACS, RIS and workflow solutions, today announced that Radisphere, the leading provider of standards-based radiology delivery solutions for health systems, has selected InteleViewer™ as its primary diagnostic viewer.

Carestream’s newest version of Image Suite Software offers a flexible image acquisition, processing and storage platform that now supports CARESTREAM wireless DR as well as CR imaging systems, and an optional mini-PACS. Image Suite offers Web-based patient scheduling, image review and reporting, and flexible archiving solutions.

Intelerad Medical Systems™, a leader in medical imaging PACS, RIS and workflow solutions, today announced the launch of InteleRIS™ 8.224, the latest version of their Reporting Information System. The solution includes a new optional Mammo Reporting Module and several new features, including enhanced scheduling, complete-and-hold function for technologists, patient-signed outside prior requests, and the ability to import PDF reports from outside systems via HL7.

Diagnostic Health (Hilton Head, S.C.), purchased CARESTREAM Vue RIS<http://www.carestream.com/vue-ris.html>, CARESTREAM Vue Cloud PACS<http://www.carestream.com/vue-cloud-based-services.html> and CARESTREAM Vue Cloud Archive<http://www.carestream.com/vue-cloud-based-services.html> to serve its five multi-modality imaging centers in Texas and Pennsylvania. The company, which is owned and operated by SDI, Inc., evaluated five suppliers prior to selecting Carestream.

Sanofi (EURONEXT:&nbsp;SAN&nbsp;and NYSE:&nbsp;SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ:&nbsp;REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. &nbsp;The mean low-density lipoprotein-cholesterol (LDL-C, or &quot;bad&quot; cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15.6%, p&lt;0.0001).&nbsp; In the trial, which employed a dose increase (up-titration) for patients who did not achieve an LDL-C level of 70 milligrams/deciliter (mg/dL), the majority of patients remained on the initial low dose of alirocumab of 75 milligrams (mg).